The VBA in Catalonia, Spain, was a pilot scheme for gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, for use in newly diagnosed or already diagnosed EGFR mutation-positive nonsmall-cell lung cancer (NSCLC) patients, and was managed by the Catalan Institute of Oncology (ICO) and the Catalan Health Service (CatSalut) (6). Here, EGFR is linked to non-small cell lung carcinoma.